Welcome messages
Presidents’ welcome message
We would like to welcome you to Paris, the magnificent capital of France.
Paris has a longstanding tradition of international exchanges. Thus, after Bern in 2004, Liverpool in 2006, it is our great pleasure to host the third international meeting on drug hypersensitivity (so called DHM3).
Recent progresses in drug hypersensitivity understanding and diagnosis have been tremendous, thanks to immunology, immunopathology, toxicology, genetic, pharmacology, pharmacogenetic, epidemiology and clinical research. This field definitely needs new ideas and connections from specialists of different backgrounds. Establishing an international network of excellent clinical and research centres devoted to drug hypersensitivities is necessary. This meeting gathers worldwide experts and actors from both academia, regulatory agencies and pharmaceutical companies. The aim of the DHM meetings is to foster the exchanges of knowledge in this exciting field.
We hope that this exchange will stimulate development in this highly interdisciplinary area of medicine and research and thus contribute to the avoidance of side effects of drugs.
Pascal Demoly
Jean-Claude Roujeau
EAACI President's welcome message
A search to drug allergy in PubMed generates more than 30,000 hits, whereas insect allergy yields 3,000 and food allergy gives rise to almost 11,000 hits. A close look to the PubMed results demonstrates that those hits indeed refer to drug hypersensitivity. Interestingly, even the search strategy to allergic asthma or allergic rhinitis does not yield so many hits. Although a very rough estimate a PubMed search gives an impression of the importance of the area.
The aim of EAACI is to promote education, training, exchange of knowledge and research in the field of Allergology and Clinical Immunology. One of my personal goals is to strengthen Clinical Allergy, the domain that comprises areas such as drug hypersensitivity, food allergy, insect allergy and immunotherapy. From this perspective endorsement of the third international meeting on drug hypersensitivity (DHM3) is a logical step. We are happy to support this meeting, as we did previously. We also value the continuous efforts of the EAACI Interest Group on Drug Allergy, chaired by Pascal Demoly to bring drug allergy to the attention of the medical community. For these reasons, also EAACI invites you to attend the DHM3.
Roy Gerth van Wijk
EAACI President